Study of REGN2810 in Adults With Cervical Cancer

Status: Active

Description

The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic platinum-refractory cervical cancer treated with either REGN2810 or investigator's choice (IC) chemotherapy. The secondary objectives are: - To compare progression-free survival (PFS) of REGN2810 versus IC chemotherapy - To compare overall response rate (ORR) (partial response [PR] + complete response [CR]) of REGN2810 versus IC chemotherapy per Response Evaluation Criteria in Solid Tumors 1.1 - To compare the duration of response (DOR) of REGN2810 versus IC chemotherapy - To compare the safety profiles of REGN2810 versus IC chemotherapy by describing adverse events (AE) - To compare quality of life (QOL) for patients treated with REGN2810 versus IC chemotherapy using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

Eligibility Criteria

Inclusion Criteria

  • Recurrent, persistent, and/or metastatic cervical cancer, for which there is not a curative intent option (surgery or radiation therapy with or without chemotherapy). Acceptable histologies are squamous carcinoma, adenocarcinoma, and adenosquamous carcinoma. Sarcomas and neuro-endocrine carcinomas are not eligible histologies.
  • Tumor progression or recurrence within 6 months of last dose of platinum therapy that was used to treat metastatic, persistent or recurrent cervical cancer
  • Patient must have measurable disease as defined by RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • ≥18 years old
  • Adequate organ or bone marrow function
  • Received prior bevacizumab therapy or had clinically documented reason why not administered
  • Received prior paclitaxel therapy or had clinically documented reason why not administered

Exclusion Criteria

  • Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments
  • Prior treatment with an agent that blocks the PD-1/PD-L1 pathway
  • Prior treatment with systemic immune modulating agents (other than anti-PD-1/PD-L1 agents) that was within 28 days prior to enrollment, or within 90 days prior to enrollment if there was an immune related adverse event, or associated with toxicity that resulted in discontinuation of the immune modulating agent
  • Active or untreated brain metastases
  • Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of study drug (REGN2810 [cemiplimab] or IC chemo
  • Active infection requiring therapy
  • History of pneumonitis within the last 5 years
  • Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
  • Concurrent malignancy other than cervical cancer and/or history of malignancy other than cervical cancer within 3 years of first planned dose of study drug (REGN2810 [cemiplimab] or IC chemo, except for tumors with negligible risk of metastasis or death. Patients with hematologic malignancies (eg, chronic lymphocytic leukemia) are excluded.

Locations & Contacts

California

Orange
UC Irvine Health / Chao Family Comprehensive Cancer Center
Status: Active
Name Not Available

Iowa

Iowa City
University of Iowa / Holden Comprehensive Cancer Center
Status: Active
Name Not Available

New York

New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase III

Trial Type

Treatment

Lead Organization

Lead Organization
Regeneron Pharmaceuticals, Inc.

Trial IDs

Primary ID R2810-ONC-1676
Secondary IDs NCI-2017-02274, 2017-000350-19
Clinicaltrials.gov ID NCT03257267